Effects of Thiazolidinedione DPP 4 Inhibitor Monotherapy and Combination Therapy with Berberine in Streptozotocin-Induced Diabetic Osteopathy

Main Article Content

Devkumar Tivari
P. V. Pakale
V. M. Thorat


The goal of this research is to compare the effectiveness of berberine with a thiazolidinedione DPP 4 inhibitor in treating streptozotocin-induced diabetic osteopathy. In this investigation, the DPP 4 inhibitor thiazolidinedione and the antioxidant berberine were given according to their published dose and administration protocols. Our results show that thiazolidinedione monotherapy upregulated in the epiphyseal area of the rat femur. This fits with the adverse impact the medication has on bone remodelling.

Article Details

How to Cite
Tivari, D. ., Pakale, P. V. ., & Thorat, V. M. . (2023). Effects of Thiazolidinedione DPP 4 Inhibitor Monotherapy and Combination Therapy with Berberine in Streptozotocin-Induced Diabetic Osteopathy. Journal of Coastal Life Medicine, 11(1), 2826–2833. Retrieved from https://www.jclmm.com/index.php/journal/article/view/763


Chen, Y. C., Hsu, C. C., Lin, Y. J., Hsu, Y. H., & Chen, C. J. (2018). The effect of pioglitazone on bone mass and turnover in postmenopausal women with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Osteoporosis International, 29(8), 1813-1821.

Huang, J., Xiao, Y., Zheng, P., Zhou, X., Chen, L., & Zeng, Z. (2016). Effects of sitagliptin on osteoblast function and bone mass in diabetic rats. Journal of Diabetes Research, 2016, 8406347.

Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., & Wang, Y. (2004). Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature Medicine, 10(12), 1344-1351.

Wang, Z. H., Hsu, H. C., Lin, J. H., Wang, C. J., Li, T. M., & Tang, F. C. (2012). Berberine prevents bone loss in streptozotocin-induced diabetic rats: a randomized, controlled trial. Journal of Bone and Mineral Research, 27(3), 746-755.

Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46:3–19.

Samtani MN. Simple pharmacometric tools for oral anti-diabetic drug development: competitive landscape for oral non-insulin therapies in type 2 diabetes. Biopharm Drug Dispos. 2010;31:162–177.

Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–2443.

Hanefeld M, Pfutzner A, Forst T, Lubben G. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Curr Med Res Opin. 2006;22:1211–1215.

Kim DJ, Lee MS, Kim KW, Lee MK. Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus. Metabolism. 2001;50:590–593.

Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J Biol Chem. 1995;270:12953–12956.

Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother. 2008;9:1087–1108.